Suven Life Sciences Completes Patient Enrollment for Ropanicant Trial
Filing Summary
Suven Life Sciences Limited has achieved full patient enrollment for its Phase-2b clinical trial of Ropanicant, a treatment for Major Depressive Disorder (MDD), ahead of schedule. The trial, conducted in the USA, involves 195 patients across 35 sites. The study is a randomized, double-blind, placebo-controlled trial with a six-week treatment duration. Topline data is anticipated by May 2026. Suven owns all intellectual property rights for Ropanicant. The company focuses on developing treatments for Central Nervous System disorders, including Alzheimer’s and Parkinson’s diseases.
Suven Life Sciences Limited has announced the completion of patient enrollment for its Phase-2b clinical trial of Ropanicant, a treatment for Major Depressive Disorder (MDD). The trial achieved its 100% patient enrollment milestone more than two months ahead of schedule. The study is being conducted exclusively in the USA and involves 195 patients across 35 sites. The trial is designed to evaluate the efficacy and safety of Ropanicant compared to a placebo over a six-week treatment period.
The Phase-2b study is a randomized, double-blind, placebo-controlled trial. It aims to assess the efficacy of Ropanicant in improving symptoms of depression, as measured by the Montgomery-Asberg Depression Rating Scale (MADRS). The trial’s rapid enrollment pace highlights strong engagement from both investigators and participating patients. Safety data is being monitored continuously, with no significant concerns reported to date.
The trial’s completion of patient enrollment ahead of schedule underscores the high level of interest from both patients and physicians in exploring new treatment options for MDD. The study’s design and execution reflect Suven’s commitment to advancing its clinical development programs efficiently. The company anticipates topline efficacy and safety results by May 2026.
Suven Life Sciences is focused on discovering and developing innovative treatments for Central Nervous System disorders. The company has a portfolio of advanced-stage clinical candidates targeting conditions such as Alzheimer’s disease, sleep disorders, and Parkinson’s disease. Suven owns all intellectual property rights for its assets in major markets, including Ropanicant, which is a novel, selective nicotinic α4β2 receptor antagonist.
The last patient out (LPO) for the Ropanicant trial is expected by the end of February 2026. The study’s successful enrollment and anticipated data readout are significant milestones in Suven’s efforts to develop new therapeutic options for MDD. The company continues to focus on advancing its clinical programs and delivering potential new treatments for patients with unmet medical needs.
Suven Life Sciences Limited is dedicated to the discovery and clinical development of innovative medicines addressing unmet medical needs in Central Nervous System disorders. The company has a robust pipeline of clinical candidates and research programs targeting various CNS disorders, including Alzheimer’s disease, Major Depressive Disorder, and Parkinson’s disease. Suven’s strategic focus is on advancing its clinical assets and expanding its research pipeline to deliver new therapeutic options.